Sector News

Merck KGaA opens $72M distribution facility at German HQ

October 22, 2018
Life sciences

Merck KGaA has opened a new distribution center as it continues to streamline its manufacturing and build up the production site at its headquarters in Darmstadt, Germany.

The €63 million ($72.3 million), 15,000 square-meter facility has eight packaging lines and robotized logistics and has the capacity to process more than 210 million boxes of medicines a year. It incorporates new technologies for tracking and tracing medicines to prevent counterfeiting and for recalls, and smart packaging to ensure more flexibility to adapt the production of medicines to patient demand.

The company said in a statement that the facility will not only handle current drugs like Merck’s Glucophage, Concor and Euthyrox, but has capacity for products in its pipeline such as evobrutinib in the area of neurology-immunology and oncology candidate tepotinib.

“Darmstadt is our prime hub for the manufacturing of medicines and it plays a key role in our plans for future growth. This latest investment in a new state-of-the-art packaging center reflects our commitment to our headquarters ….” CEO Stefan Oschmann said in a statement.

The company said the new facility is part of the broader €1 billion investment through 2020 to transform the Darmstadt site into contemporary global headquarters.

It is also part of a remaking of Merck’s manufacturing. Last year, it said it would invest more than $100 million on four sites in Germany, Switzerland and France, but would close sites in Steinheim, Eppelheim, Hohenbrunn and Berlin, all in Germany. Beginning in 2019, it will move operations from those sites to other facilities, a process that is slated to be complete in 2022. The company said there will be a net loss of about 200 jobs. It said the move were needed to streamlines its European production.

By Eric Palmer

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).